Drug intelligence / Profile preview

YZJT-1705

Development stage: Unknown
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Injection, Subcutaneous (supported By Trial Design)[1]

Overview

YZJT-1705 is an investigational drug developed for postoperative analgesia, specifically targeting pain management in patients undergoing abdominal surgery. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics (PK), and efficacy as an analgesic. The drug is administered as an injection and has been compared to ropivacaine hydrochloride injection in clinical studies. The primary developer is the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, with Jiangsu Yangtze River Pharmaceutical Group also involved in sponsorship and development activities[1]. Its precise mechanism of action or molecular target has not been publicly disclosed.

Beyond the preview

Go deeper on YZJT-1705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZJT-1705.

Explore the full profile